ShawnXiaoYuMDPhD

Hematology/Oncology

Hematology/Oncology Fellow at University of North Carolina

Dr. Yu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

I am a physician scientist trained in hematology/oncology, clinical pharmacology, and protein science, seeking to engineer novel protein-based immunotherapies for the fight against cancer.

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2022 - 2025
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2019 - 2022
University of Washington School of MedicineClass of 2019
University of WashingtonPh.D., Bioengineering, 2008 - 2015
California Institute of TechnologyB.S., Chemical Engineering, 2004 - 2008

Fred J. Ansfield, MD, Endowed Young Investigator Award Conquer Cancer Foundation, American Society of Clinical Oncology, 2024
Alexander Grinstein Endowed Fellowship University of Washington, 2009
Upper Class Merit Award, Carnation Scholarship California Institute of Technology, 2007-2008
Amgen Scholar Amgen Foundation, 2007
William N. Lacey Summer Undergraduate Research Fellowship California Institute of Technology, 2006
Summer Undergraduate Research Fellowship California Institute of Technology, 2005
Join now to see all

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Start of enrollment: 2017 Mar 28
Active, not recruiting
Early Phase 1

PubMed

288 citations
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva, Shawn Yu, Umut Ulge, Jamie B. Spangler, Kevin Jude
Nature. 2019-01-09
1 citations
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
Shawn Yu, Menggang Yu, Barry Keane, David M Mauro, Paul R Helft
The Oncologist. 2024-03-04

Abstracts/Posters

Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE)
Peter Zang, Karen Resnick, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Varsha Tulpule, Anishka D'souza, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors
Karen Resnick, Peter Zang, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Trevor E Angell, Jacob Stephen Thomas, Jorge J. Nieva, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
Venous thromboembolism in patients on check point inhibitors
Upama Giri, Xiao Yu, Karen Resnick, Travis Larsen, and Gino Kim In, Journal of Clinical Oncology, 5/28/2021

Other

De novo design of potent and selective interleukin mimetics
Silva Manzano, D. A.; Yu, S.; Ulge, U.; Baker, D.; Garcia, K. C.; Spangler, J.; Walkey, C.; Rubio, A. Q.; Weitzner, B., US 11117944 B2
https://lens.org/080-135-637-654-248
9/14/2021

Young Investigator AwardConquer Cancer, the ASCO Foundation2024–2025
Multispecific T-cell engagers targeting intracellular cancer-testis antigens in urothelial carcinomaNC TraCS2024–2025
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training ProgramNational Institute of General Medical Sciences2023–2024

Postdoctoral FellowUNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program, Brian Kuhlman and William Kim2023 - 2025
Postdoctoral FellowUniversity of Washington, David Baker2017 - 2018